Cargando…

Pharmacokinetic Data of Dolutegravir in Second-line Treatment of Children With Human Immunodeficiency Virus: Results From the CHAPAS4 Trial

BACKGROUND: Dolutegravir (DTG), combined with a backbone of 2 nucleoside reverse transcriptase inhibitors, is currently the preferred first-line treatment for human immunodeficiency virus (HIV) in childhood. CHAPAS4 is an ongoing randomized controlled trial investigating second-line treatment option...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bevers, Lisanne A H, Waalewijn, Hylke, Szubert, Alexander J, Chabala, Chishala, Bwakura-Dangarembizi, Mutsa, Makumbi, Shafic, Nangiya, Joan, Mumbiro, Vivian, Mulenga, Veronica, Musiime, Victor, Burger, David M, Gibb, Diana M, Colbers, Angela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640690/ https://www.ncbi.nlm.nih.gov/pubmed/37280040 http://dx.doi.org/10.1093/cid/ciad346

Ejemplares similares

First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial
por: Waalewijn, Hylke, et al.
Publicado: (2023)

Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and Adolescents
por: Chandasana, Hardik, et al.
Publicado: (2023)

Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial
por: Turkova, Anna, et al.
Publicado: (2022)

Optimizing Clinical Trial Design to Maximize Evidence Generation in Pediatric HIV
por: Ford, Deborah, et al.
Publicado: (2018)

Baseline Inflammatory Biomarkers Identify Subgroups of HIV-Infected African Children With Differing Responses to Antiretroviral Therapy
por: Prendergast, Andrew J., et al.
Publicado: (2016)

Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial
por: Waalewijn, Hylke, et al.
Publicado: (2022)

Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial
por: Mulenga, Veronica, et al.
Publicado: (2016)

Bone mineral density among children living with HIV failing first-line anti-retroviral therapy in Uganda: A sub-study of the CHAPAS-4 trial
por: Natukunda, Eva, et al.
Publicado: (2023)

Chapas : un diseño redondo
por: King, Laurence
Publicado: (2007)

Adequate exposure of 50 mg dolutegravir in children weighing 20 to 40 kg outside of sub-Sahara Africa
por: Waalewijn, Hylke, et al.
Publicado: (2022)

Marginal structural models for repeated measures where intercept and slope are correlated: An application exploring the benefit of nutritional supplements on weight gain in HIV-infected children initiating antiretroviral therapy
por: Farmer, Ruth E., et al.
Publicado: (2020)

Martha Chapa : hacia otro paraíso /
por: Henestrosa, Andrés, 1906-2008
Publicado: (1997)

Granados Chapa : un periodista en contexto /
por: Musacchio, Humberto, 1943-
Publicado: (2010)

Pubertal development in HIV-infected African children on first-line antiretroviral therapy
por: Szubert, Alexander J., et al.
Publicado: (2015)

Las cubiertas de chapa /
por: Paricio, Ignacio
Publicado: (1999)

Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial
por: Bollen, Pauline D J, et al.
Publicado: (2020)

Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational analyses within the randomised ARROW trial
por: Szubert, Alexander J., et al.
Publicado: (2017)

The cost‐effectiveness of prophylaxis strategies for individuals with advanced HIV starting treatment in Africa
por: Walker, Simon M, et al.
Publicado: (2020)

“I don't feel shy because I will be among others who are just like me…”: The role of support groups for children perinatally infected with HIV in Zimbabwe
por: Mupambireyi, Zivai, et al.
Publicado: (2014)

Optimizing Pediatric Dosing Recommendations and Treatment Management of Antiretroviral Drugs Using Therapeutic Drug Monitoring Data in Children Living With HIV
por: Waalewijn, Hylke, et al.
Publicado: (2019)

Miguel Angel Granados Chapa : maestro y periodista /
Publicado: (2008)

Pharmacokinetics of Zidovudine Dosed Twice Daily According to World Health Organization Weight Bands in Ugandan HIV-infected Children
por: Fillekes, Quirine, et al.
Publicado: (2014)

Miguel Ángel Granados Chapa : (1941-2011).
Publicado: (2013)

Factors Associated With Weight Gain in People Treated With Dolutegravir
por: Taramasso, Lucia, et al.
Publicado: (2020)

Pharmacokinetics of First-Line Drugs in Children With Tuberculosis, Using World Health Organization–Recommended Weight Band Doses and Formulations
por: Chabala, Chishala, et al.
Publicado: (2021)

Prevalence of Lipodystrophy and Metabolic Abnormalities in HIV-infected African Children after 3 Years on First-line Antiretroviral Therapy
por: Bwakura-Dangarembizi, Mutsawashe, et al.
Publicado: (2015)

Reduced bacterial skin infections in HIV-infected African children randomized to long-term cotrimoxazole prophylaxis
por: Prendergast, Andrew J., et al.
Publicado: (2016)

Ethical and legal constraints to children’s participation in research in Zimbabwe: experiences from the multicenter pediatric HIV ARROW trial
por: Bwakura-Dangarembizi, Mutsa, et al.
Publicado: (2012)

Outcomes of Bariatric Surgery in People With Human Immunodeficiency Virus: A Retrospective Analysis From the ATHENA Cohort
por: Zino, Leena, et al.
Publicado: (2023)

Raltegravir-based Postnatal HIV Prophylaxis Therapy in a Neonate After in Utero Dolutegravir Exposure
por: Jacobs, Tom G., et al.
Publicado: (2022)

Immunological, Cognitive, and Psychiatric Outcomes After Initiating Efavirenz- and Dolutegravir-based Antiretroviral Therapy During Acute Human Immunodeficiency Virus Infection
por: Chan, Phillip, et al.
Publicado: (2022)

First-Line Antituberculosis Drug Concentrations in Infants With HIV and a History of Recent Admission With Severe Pneumonia
por: Chabala, Chishala, et al.
Publicado: (2023)

Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy
por: Crook, Angela M., et al.
Publicado: (2016)

Effect of handrubbing using locally-manufactured alcohol-based handrubs in paediatric wards in Harare, Zimbabwe
por: Gudza-Mugabe, Muchaneta, et al.
Publicado: (2017)

Carriage of antibiotic-resistant Enterobacteriaceae in hospitalised children in tertiary hospitals in Harare, Zimbabwe
por: Magwenzi, Marcelyn T., et al.
Publicado: (2017)

Brief Report: Suboptimal Lopinavir Exposure in Infants on Rifampicin Treatment Receiving Double-dosed or Semisuperboosted Lopinavir/Ritonavir: Time for a Change
por: Jacobs, Tom G., et al.
Publicado: (2023)

Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks
por: Rolle, Charlotte-Paige, et al.
Publicado: (2023)

Impact of Obesity on the Drug–Drug Interaction Between Dolutegravir and Rifampicin or Any Other Strong Inducers
por: Berton, Mattia, et al.
Publicado: (2023)

Absence of Proviral Human Immunodeficiency Virus (HIV) Type 1 Evolution in Early-Treated Individuals With HIV Switching to Dolutegravir Monotherapy During 48 Weeks
por: Jörimann, Lisa, et al.
Publicado: (2023)

Diseño de útiles de procesado de chapa y estampación /
por: Marín García, Juan Manuel
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9ee0iuot9e89s0c8d6qr4c0rqh